Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Comparison between the therapeutic effect of metformin, glimepiride and their combination as an add-on treatment to insulin glargine in uncontrolled patients with type 2 diabetes.

Park CY, Kang JG, Chon S, Noh J, Oh SJ, Lee CB, Park SW.

PLoS One. 2014 Mar 10;9(3):e87799. doi: 10.1371/journal.pone.0087799.

3.

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea.

Weissman PN, Carr MC, Ye J, Cirkel DT, Stewart M, Perry C, Pratley R.

Diabetologia. 2014 Dec;57(12):2475-84. doi: 10.1007/s00125-014-3360-3.

PMID:
25208756
4.

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.

Diabetes Care. 2005 Feb;28(2):254-9.

PMID:
15677775
5.

The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.

Moon JS, Ha KS, Yoon JS, Lee HW, Lee HC, Won KC; BETA study group..

Acta Diabetol. 2014 Apr;51(2):277-85. doi: 10.1007/s00592-013-0553-z.

PMID:
24445656
6.

Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.

Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G.

Diabetes Care. 2006 Mar;29(3):554-9.

PMID:
16505505
7.

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2).

Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V.

Diabetes Care. 2015 Dec;38(12):2241-9. doi: 10.2337/dc14-1625.

PMID:
26089386
8.

Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.

Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.

Ann Intern Med. 2008 Oct 21;149(8):531-9.

PMID:
18936501
10.

Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.

Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, Pilorget V, Dain MP, Riddle MC.

Diabetes Obes Metab. 2015 Jan;17(1):15-22. doi: 10.1111/dom.12329.

13.
14.
15.

Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.

Schernthaner G, Rosas-Guzmán J, Dotta F, Guerci B, Simó R, Festa A, Kiljański J, Zhou M, Gallwitz B.

Diabetes Obes Metab. 2015 Jul;17(7):689-98. doi: 10.1111/dom.12471.

PMID:
25846577
16.

Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.

Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, Ramirez LA, Jimenez J; HOE 901/4013 LA Study Group..

Arch Med Res. 2006 May;37(4):495-501.

PMID:
16715577
18.

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group..

Diabetologia. 2009 Oct;52(10):2046-55. doi: 10.1007/s00125-009-1472-y.

19.

Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.

Hong AR, Lee J, Ku EJ, Hwangbo Y, Kim KM, Moon JH, Choi SH, Jang HC, Lim S.

Diabetes Res Clin Pract. 2015 Jul;109(1):141-8. doi: 10.1016/j.diabres.2015.04.019.

PMID:
26003889
20.
Items per page

Supplemental Content

Support Center